Compass Therapeutics, Inc. (Nasdaq: CMPX) will announce financial results for the quarter ended June 30, 2025, and provide updates on ongoing clinical studies on August 11, 2025, at 8:00 a.m. ET. The webcast and conference call will discuss the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726. Dial 1-877-407-9716 (US) or 1-201-493-6779 (International) with the conference ID 13754954 to join. A replay will be available for 90 days. Compass Therapeutics focuses on developing antibody-based therapeutics for oncology and other diseases by targeting critical biological pathways. Founded in 2014, the company is headquartered in Boston, Massachusetts. For more information, visit https://www.compasstherapeutics.com.

Read more at GlobeNewswire: Compass Therapeutics to Present Second Quarter Financial